C-reactive protein as a novel biomarker

References

• Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol 1999; 10(5): 435–41
   PubMed Web of Science ®Google Scholar
• Zhang YX, Cliff WJ, Schoefl GI, et al. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145(2): 375–9
   PubMed Web of Science ®Google Scholar
• Albert MA. The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 2000; 2(4): 274–9
   Google Scholar
• Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 2001; 47(3): 403–11
   Google Scholar
• Araneda M, Krishnan V, Hall K, et al. Reactive and clonal thrombocytosis: proinflammatory and hematopoietic cytokines and acute phase proteins. South Med J 2001; 94(4): 417–20
   Google Scholar
• Zhu J, Quyyumi AA, Norman JE, et al. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol 1999; 34(6): 1738–43
   Google Scholar
• Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103(1): 45–51
   PubMed Web of Science ®Google Scholar
• Morrow D, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31(7): 1460–5
   PubMedGoogle Scholar
• Bogaty P, Poirier P, Simard S, et al. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001; 103(25): 3062–8
   Google Scholar
• Bazzino O, Ferreirós ER, Pizarra R, et al. C-reactive protein and the stress tests for the risk stratification of patients recovering from unstable angina pectoris. Am J Cardiol 2001; 87(11): 1235–9
   Web of Science ®Google Scholar
• Bolibar I, von Eckardstein A, Assmann G, et al. Short-term prognostic value of lipid measurements in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb Haemost 2000; 84(6): 955–60
   Google Scholar
• Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99(2): 237–42
   PubMed Web of Science ®Google Scholar
• Haverkate F, Thompson SG, Duckert F. Haemostasis factors in angina pectoris; relation to gender, age and acute-phase reaction. Results of the ECAT Angina Pectoris Study Group. Thromb Haemost 1995; 73(4): 561–7
   Google Scholar
• Moukarbel GV, Arnaout MS, Alam SE. C-reactive protein is a marker for a complex culprit lesion anatomy in unstable angina. Clin Cardiol 2001; 24(7): 506–10
   Google Scholar
• Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998; 82(4): 515–8
   PubMed Web of Science ®Google Scholar
• Milazzo D, Biasucci LM, Luciani N, et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events. Am J Cardiol 1999; 84(4): 459–61, A9
   Google Scholar
• Eisenberg MS, Chen HJ, Warshofsky MK, et al. Elevated levels of plasma C-reactive protein are associated with decreased graft survival in cardiac transplant recipients. Circulation 2000; 102(17): 2100–4
   PubMed Web of Science ®Google Scholar
• Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vase Biol 1998; 18(11): 1671–8
   PubMed Web of Science ®Google Scholar
• Sacks FM, Ridker PM. Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Herz 1999; 24(1): 51–6
   Google Scholar
• Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286(1): 64–70
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-teactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344(26): 1959–65
   PubMed Web of Science ®Google Scholar
• Markwood TT, Kent SM, Coyle LC, et al. Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)—a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intimamedia thickness. Am Heart J 2001; 141(3): 342–7
   Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336(14): 973–9
   PubMed Web of Science ®Google Scholar
• Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100(8): 793–8
   PubMed Web of Science ®Google Scholar
• Kennon S, Price CP, Mills PG, et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001; 37(5): 1266–70
   Google Scholar